Interestingly, the combination was previously found to be ineffective in MGMT‐unmethylated cell lines, suggesting the predicting value of MGMT promoter methylation status in tumor response to TMZ/veliparib combination therapy.357. This evidence concerns the gene MGMT and neoplasm.